Ultragenyx Pharmaceutical Inc (RARE.OQ)
23 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2015||Independent Chairman of the Board|
|57||President, Chief Executive Officer, Director|
|42||2016||Chief Financial Officer, Executive Vice President|
|47||2017||President - Research and Development|
|39||2016||Executive Vice President, General Counsel|
- BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301
- BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children
- BRIEF-Ultragenyx Reports Q4 Loss Per Share $1.89
- BRIEF-Ultragenyx Prices Public Offering Of 4.39 Mln Common Shares At $57/Share
- BRIEF-Ultragenyx Announces Proposed Public Offering Of Common Stock